Ratings by Chardan (Gbola Amusa)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/11/2026 | Kodiak Sciences Inc. | KOD | Upgrade | Buy (Neutral) |
41.01 (39.28) |
-4.22% | Details | |
| 4/21/2026 | Passage Bio Inc. | PASG | Downgrade | Neutral (Buy) |
11.67 (4.60) |
-60.58% | Details | |
| 3/4/2025 | Passage Bio Inc. | PASG | Maintain | Buy (N/A) |
|
Details | ||
| 8/7/2023 | Passage Bio Inc. | PASG | Maintain | Buy (N/A) |
|
Details | ||
| 7/25/2023 | Kodiak Sciences Inc. | KOD | Downgrade | Neutral (Buy) |
3.94 (41.01) |
940.86% | Details | |
| 3/30/2023 | Taysha Gene Therapies | TSHA | Maintain | Buy (N/A) |
|
Details | ||
| 12/14/2022 | Moderna | MRNA | Downgrade | Neutral (Buy) |
197.54 (74.50) |
-62.29% | Details | |
| 10/25/2022 | Applied Genetic Technologies Corp. | AGTC | Downgrade | Neutral (Buy) |
0.24 (0.39) |
62.5% | Details | |
| 12/23/2021 | LogicBio Therapeutics | LOGC | Maintain | Buy (N/A) |
|
Details | ||
| 5/28/2021 | Provention Bio Inc. | PRVB | Maintain | Buy (N/A) |
|
Details | ||
| 4/29/2021 | Adverum Biotechnologies | ADVM | Downgrade | Neutral (Buy) |
10.16 (4.18) |
-58.86% | Details | |
| 4/12/2021 | Taysha Gene Therapies | TSHA | Maintain | Buy (N/A) |
|
Details | ||
| 4/12/2021 | Provention Bio Inc. | PRVB | Maintain | Buy (N/A) |
|
Details | ||
| 3/16/2021 | Solid Biosciences | SLDB | Maintain | Buy (N/A) |
|
Details | ||
| 3/8/2021 | Passage Bio Inc. | PASG | Maintain | Buy (N/A) |
|
Details | ||
| 3/5/2021 | Seres Therapeutics | MCRB | Upgrade | Buy (Neutral) |
18.11 (8.29) |
-54.22% | Details | |
| 3/4/2021 | Taysha Gene Therapies | TSHA | Maintain | Buy (N/A) |
|
Details | ||
| 1/15/2021 | Krystal Biotech | KRYS | Maintain | Buy (N/A) |
|
Details | ||
| 1/8/2021 | Solid Biosciences | SLDB | Maintain | Buy (N/A) |
|
Details | ||
| 1/4/2021 | Provention Bio Inc. | PRVB | Maintain | Buy (N/A) |
|
Details | ||
| 12/17/2020 | MeiraGTx Holdings plc | MGTX | Maintain | Buy (N/A) |
|
Details | ||
| 11/12/2020 | Immunovant | IMVT | Maintain | Buy (N/A) |
|
Details | ||
| 10/19/2020 | Taysha Gene Therapies | TSHA | New Coverage | Buy (N/A) |
21.80 (6.34) |
-70.92% | Details | |
| 10/1/2020 | Solid Biosciences | SLDB | Maintain | Buy (N/A) |
|
Details | ||
| 8/25/2020 | Immunovant | IMVT | Maintain | Buy (N/A) |
|
Details | ||
| 8/13/2020 | Immunovant | IMVT | Maintain | Buy (N/A) |
|
Details | ||
| 8/4/2020 | Regenxbio Inc. | RGNX | Maintain | Buy (N/A) |
|
Details | ||
| 7/15/2020 | Moderna | MRNA | Maintain | Buy (N/A) |
|
Details | ||
| 4/28/2020 | Moderna | MRNA | Maintain | Buy (N/A) |
|
Details | ||
| 3/10/2020 | Krystal Biotech | KRYS | Maintain | Buy (N/A) |
|
Details | ||
| 3/3/2020 | uniQure BV | QURE | Maintain | Buy (N/A) |
|
Details | ||
| 2/10/2020 | Adverum Biotechnologies | ADVM | Upgrade | Buy (Neutral) |
10.24 (10.16) |
-0.78% | Details | |
| 2/6/2020 | Applied Genetic Technologies Corp. | AGTC | Maintain | Buy (N/A) |
|
Details | ||
| 1/31/2020 | Esperion Therapeutics | ESPR | Maintain | Neutral (N/A) |
|
Details | ||
| 1/30/2020 | Regenxbio Inc. | RGNX | Maintain | Buy (N/A) |
|
Details | ||
| 1/9/2020 | Immunovant | IMVT | New Coverage | Buy (N/A) |
15.27 (39.23) |
156.91% | Details | |
| 12/4/2019 | Audentes Therapeutics | BOLD | Downgrade | Neutral (Buy) |
58.93 (2.45) |
-95.84% | Details | |
| 12/2/2019 | Kodiak Sciences Inc. | KOD | Maintain | Buy (N/A) |
|
Details | ||
| 11/26/2019 | The Medicines Company | MDCO | Downgrade | Neutral (Buy) |
83.80 (84.90) |
1.31% | Details | |
| 11/5/2019 | Krystal Biotech | KRYS | Maintain | Buy (N/A) |
|
Details | ||
| 10/23/2019 | Provention Bio Inc. | PRVB | Maintain | Buy (N/A) |
|
Details | ||
| 10/15/2019 | Kodiak Sciences Inc. | KOD | Maintain | Buy (N/A) |
|
Details | ||
| 9/23/2019 | MeiraGTx Holdings plc | MGTX | Maintain | Buy (N/A) |
|
Details | ||
| 9/3/2019 | Audentes Therapeutics | BOLD | Maintain | Buy (N/A) |
|
Details | ||
| 9/3/2019 | Applied Genetic Technologies Corp. | AGTC | Upgrade | Buy (Neutral) |
3.16 (0.39) |
-87.66% | Details | |
| 8/16/2019 | Solid Biosciences | SLDB | Upgrade | Buy (Neutral) |
6.15 (10.73) |
74.47% | Details | |
| 7/22/2019 | VistaGen Therapeutics | VTGN | Downgrade | Neutral (Buy) |
0.63 (0.23) |
-63.49% | Details | |
| 6/24/2019 | Krystal Biotech | KRYS | Maintain | Buy (N/A) |
|
Details | ||
| 6/17/2019 | Voyager Therapeutics | VYGR | Maintain | Neutral (N/A) |
|
Details | ||
| 6/5/2019 | Regenxbio Inc. | RGNX | Maintain | Buy (N/A) |
|
Details | ||
| 5/22/2019 | Tocagen Inc. | TOCA | Maintain | Buy (N/A) |
|
Details | ||
| 5/16/2019 | uniQure BV | QURE | Maintain | Buy (N/A) |
|
Details | ||
| 5/14/2019 | Solid Biosciences | SLDB | Downgrade | Neutral (Buy) |
8.85 (6.15) |
-30.51% | Details | |
| 4/5/2019 | Moderna | MRNA | New Coverage | Buy (N/A) |
21.33 (197.54) |
826.11% | Details | |
| 3/12/2019 | Krystal Biotech | KRYS | Maintain | Buy (N/A) |
|
Details | ||
| 3/11/2019 | Axovant Gene Therapies Ltd. | AXGT | Upgrade | Buy (Neutral) |
1.48 (2.10) |
41.89% | Details | |
| 3/4/2019 | uniQure BV | QURE | Maintain | Buy (N/A) |
|
Details | ||
| 2/28/2019 | Tocagen Inc. | TOCA | Maintain | Buy (N/A) |
|
Details | ||
| 2/27/2019 | MeiraGTx Holdings plc | MGTX | Maintain | Buy (N/A) |
|
Details | ||
| 2/25/2019 | Audentes Therapeutics | BOLD | Upgrade | Buy (Neutral) |
25.74 (58.93) |
128.94% | Details | |
| 2/20/2019 | Kodiak Sciences Inc. | KOD | New Coverage | Buy (N/A) |
6.83 (39.28) |
475.11% | Details | |
| 1/9/2019 | uniQure BV | QURE | Maintain | Buy (N/A) |
|
Details | ||
| 11/13/2018 | LogicBio Therapeutics | LOGC | New Coverage | Buy (N/A) |
15.11 (7.06) |
-53.28% | Details | |
| 11/7/2018 | uniQure BV | QURE | Maintain | Buy (N/A) |
|
Details | ||
| 11/2/2018 | Adverum Biotechnologies | ADVM | Maintain | Neutral (N/A) |
|
Details | ||
| 9/11/2018 | Applied Genetic Technologies Corp. | AGTC | Downgrade | Neutral (Buy) |
4.47 (3.16) |
-29.31% | Details | |
| 8/30/2018 | Tocagen Inc. | TOCA | New Coverage | Buy (N/A) |
8.53 (0.93) |
-89.1% | Details | |
| 8/23/2018 | MeiraGTx Holdings plc | MGTX | New Coverage | Buy (N/A) |
10.01 (4.92) |
-50.85% | Details | |
| 8/17/2018 | Amicus Therapeutics | FOLD | Downgrade | Neutral (Buy) |
13.39 (14.49) |
8.22% | Details |
